13.09.2022 Views

Molecular Biology of the Cell by Bruce Alberts, Alexander Johnson, Julian Lewis, David Morgan, Martin Raff, Keith Roberts, Peter Walter by by Bruce Alberts, Alexander Johnson, Julian Lewis, David Morg

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

CANCER-CRITICAL GENES: HOW THEY ARE FOUND AND WHAT THEY DO

1109

HEALTHY CELL WITH ONLY ONE NORMAL Rb GENE COPY

mutation at Rb locus

in maternal chromosome

nondisjunction

causes

chromosome

loss

chromosome

loss, then

chromosome

duplication

normal Rb gene

in paternal chromosome

POSSIBLE WAYS OF ELIMINATING NORMAL Rb GENE

mitotic

recombination

event

gene

conversion

during mitotic

recombination

deletion

point

mutation

Figure 20–21 Six ways of losing the

remaining good copy of a tumor

suppressor gene through a change in

DNA sequences. A cell that is defective

in only one of its two copies of a tumor

suppressor gene—for example, the Rb

gene—usually behaves as a normal,

healthy cell; the diagrams below show how

this cell may lose the function of the other

gene copy as well and thereby progress

toward cancer. A seventh possibility,

frequently encountered with some tumor

suppressors, is that the gene may be

silenced by an epigenetic change, without

alteration of the DNA sequence,

as illustrated in Figure 20–22. (After

W.K. Cavenee et al., Nature 305:779–784,

1983. With permission from Macmillan

Publishers Ltd.)

the chromosome carrying the remaining normal copy may be lost from the cell

through errors in chromosome segregation; or the normal gene, along with

neighboring genetic material, may be replaced by a mutant version through

either a mitotic recombination event or a gene conversion that accompanies it (see

MBoC6 m20.31/20.21

p. 286).

Figure 20–21 summarizes the range of ways in which the remaining good copy

of a tumor suppressor gene can be lost through a DNA sequence change, using the

Rb gene as an example. It is important to note that, except for the point mutation

mechanism illustrated at the far right, these pathways all produce cells that carry

only a single type of DNA sequence in the chromosomal region containing their

Rb genes—a sequence that is identical to the sequence in the original mutant

chromosome.

Epigenetic changes provide another important way to permanently inactivate

a tumor suppressor gene. Most commonly, the gene may become packaged into

heterochromatin and/or the C nucleotides in CG sequences in its promoter may

become methylated in a heritable manner (see pp. 404–405). These mechanisms

can irreversibly silence the gene in a cell and in all of its progeny. Analysis of methylation

patterns in cancer genomes shows that epigenetic gene silencing is a frequent

event in tumor progression, and epigenetic mechanisms are now thought

to help inactivate several different tumor suppressor genes in most human cancers

(Figure 20–22).

Systematic Sequencing of Cancer Cell Genomes Has Transformed

Our Understanding of the Disease

Methods such as those we have described above shone a spotlight on a set of cancer-critical

genes that were identified in a piecemeal fashion. Meanwhile, the rest

of the cancer cell genome remained in darkness: it was a mystery how many other

mutations might lurk there, of what types, in which varieties of cancer, at what

frequencies, with what variations from patient to patient, and with what consequences.

With the sequencing of the human genome and the dramatic advances

in DNA sequencing technology (see Panel 8–1, pp. 478–481), it has become possible

to see the whole picture—to view cancer cell genomes in their entirety. This

transforms our understanding of the disease.

Cancer cell genomes can be scanned systematically in several different ways.

At one extreme—the most costly, but no longer prohibitively so—one can determine

a tumor’s complete genome sequence. More cheaply, one can focus just on

the 21,000 or so genes in the human genome that code for protein (the so-called

exome), looking for mutations in the cancer cell DNA that alter the amino acid

sequence of the product or prevent its synthesis (Figure 20–23). There are also

efficient techniques to survey the genome for regions that have undergone

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!